{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T03:55:29Z","timestamp":1769831729002,"version":"3.49.0"},"reference-count":22,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"unspecified","delay-in-days":178,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines & Immunotherapeutics"],"published-print":{"date-parts":[[2021,4,3]]},"DOI":"10.1080\/21645515.2020.1804247","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T18:08:48Z","timestamp":1600884528000},"page":"1205-1210","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018\/2019 season"],"prefix":"10.1080","volume":"17","author":[{"given":"Laurence","family":"Serradell","sequence":"first","affiliation":[{"name":"Risk-Benefit & Epidemiology, Sanofi Pasteur, Campus Sanofi Lyon, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Wagu\u00e9","sequence":"additional","affiliation":[{"name":"Medical Operations, Sanofi Pasteur, Campus Sanofi Lyon, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5306-2833","authenticated-orcid":false,"given":"Annick","family":"Moureau","sequence":"additional","affiliation":[{"name":"Global Biostatistical Sciences, Sanofi Pasteur, Marcy l\u2019Etoile France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3327-0141","authenticated-orcid":false,"given":"Markku","family":"Nissil\u00e4","sequence":"additional","affiliation":[{"name":"Terveystalo Clinical Research and Biobank, Turku, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Laure","family":"Chabanon","sequence":"additional","affiliation":[{"name":"Global Pharmacovigilance, Sanofi Pasteur, Campus Sanofi Lyon, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"key":"e_1_3_3_2_1","first-page":"461","article-title":"Vaccines against influenza WHO position paper - November 2012","volume":"87","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec. 2012;87:461\u201376.","journal-title":"Wkly Epidemiol Rec"},{"key":"e_1_3_3_3_1","unstructured":"European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU. London; 2014 Apr 10 [accessed 2019 Oct 14]. https:\/\/www.ema.europa.eu\/en\/interim-guidance-enhanced-safety-surveillance-seasonal-influenza-vaccines-eu."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.34369"},{"key":"e_1_3_3_5_1","first-page":"294","article-title":"Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria","volume":"35","author":"Clothier HJ","year":"2011","unstructured":"Clothier HJ, Crawford NW, Kempe A, Buttery JP. Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria. Commun Dis Intell Q Rep. 2011;35:294\u201398.","journal-title":"Commun Dis Intell Q Rep"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.34360"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1324302"},{"key":"e_1_3_3_8_1","first-page":"22","article-title":"Passive enhanced safety surveillance for Vaxigrip and Intanza 15 \u00b5g in the United Kingdom and Finland during the northern hemisphere influenza season 2015\/16","author":"Bricout H","year":"2017","unstructured":"Bricout H, Chabanon AL, Souverain A, Sadorge C, Vesikari T, Caroe TD. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 \u00b5g in the United Kingdom and Finland during the northern hemisphere influenza season 2015\/16. Euro Surveill. 2017;18:22.","journal-title":"Euro Surveill"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1405882"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1581538"},{"key":"e_1_3_3_11_1","unstructured":"World Medical Association. Declaration of Helsinki; [accessed 2020 Jun 11]. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/."},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-019-00500-x"},{"key":"e_1_3_3_13_1","unstructured":"European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ENCePP guide on methodological standards in pharmacoepidemiology; [accessed 2020 Jun 11]. http:\/\/www.encepp.eu\/standards_and_guidances\/methodologicalGuide.shtml."},{"key":"e_1_3_3_14_1","unstructured":"Datapharm Electonic Medicines Compendium. Summary of product characteristics: quadrivalent influenza vaccine (Split virion inactivated); 2019 May 29 [accessed 2019 Oct 14]. https:\/\/www.medicines.org.uk\/emc\/product\/666\/smpc."},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1407650"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1565258"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0747-4"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.11.071"},{"key":"e_1_3_3_19_1","unstructured":"Vaccines Today. Finland: no jab no job? 2019 Dec 21 [accessed 2019 Oct 14]. https:\/\/www.vaccinestoday.eu\/stories\/finland-no-jab-no-job\/."},{"key":"e_1_3_3_20_1","doi-asserted-by":"crossref","unstructured":"Larson H de Figueiredo A Karafllakis E Rawal M The state of vaccine confidence in the EU: 2018. Luxembourg; [accessed 2019 Oct 14]. https:\/\/ec.europa.eu\/health\/sites\/health\/files\/vaccination\/docs\/2018_vaccine_confidence_en.pdf.","DOI":"10.1093\/eurpub\/ckz185.374"},{"key":"e_1_3_3_21_1","first-page":"1","article-title":"Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS)\u2013United States, 1991-2001","volume":"52","author":"Zhou W","year":"2003","unstructured":"Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, et al. Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS)\u2013United States, 1991-2001. MMWR Surveill Summ. 2003;52:1\u201324.","journal-title":"MMWR Surveill Summ"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja16.01371"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023263"}],"container-title":["Human Vaccines & Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2020.1804247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T14:51:00Z","timestamp":1709304660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2020.1804247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4,3]]}},"alternative-id":["10.1080\/21645515.2020.1804247"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2020.1804247","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-04-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}